Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7M4\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml75TWM2OD1yLkC4NlMyKCEQvF2=NEfsPHNUSU6JRWK=
SW756M{jMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTxO|VKSzVyPUCuNVQxOjRiIN88US=>M3ywOnNCVkeHUh?=
CTV-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGT5N2dKSzVyPUCuNVY{QThiIN88US=>MkHVV2FPT0WU
HSC-4NUDEdnNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoiwTWM2OD1yLkG3NVU5KCEQvF2=NXT3NFNVW0GQR1XS
LAMA-84M3TCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7NTWM2OD1yLkK4OlY1KCEQvF2=MY\TRW5ITVJ?
KU812MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{izb2lEPTB;MD6zOFA3QCBizszNMl65V2FPT0WU
HCC1806NV\nXmRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTBwM{WyNVYhKM7:TR?=Ml\TV2FPT0WU
DOKNYr0TWVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlfsTWM2OD1yLkO3O|g3KCEQvF2=M2DqN3NCVkeHUh?=
NCI-H209M{PmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHQTWM2OD1yLkSwPFA5KCEQvF2=M4fQTXNCVkeHUh?=
EoL-1-cellMlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDMTWM2OD1yLkSxOVc3KCEQvF2=NGXROmtUSU6JRWK=
H9M1XtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjlS4p2UUN3ME2wMlQ{PDZ2IDFOwG0>NYizNG84W0GQR1XS
EM-2Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjhbWRjUUN3ME2wMlQ{QDliIN88US=>NYr0V4twW0GQR1XS
NCI-H292M3zEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXlSoxqUUN3ME2wMlQ1OTB6IDFOwG0>NWjxUIlwW0GQR1XS
697MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTBwNEW2N|MhKM7:TR?=MmHxV2FPT0WU
BHT-101M2fVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mme1TWM2OD1yLkS2OVkhKM7:TR?=MUPTRW5ITVJ?
BE-13MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\zTWM2OD1yLkS4OVczKCEQvF2=MlrNV2FPT0WU
RS4-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPEe2RCUUN3ME2wMlQ5PTh2IDFOwG0>MVHTRW5ITVJ?
IGROV-1MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTBwNEi3PVchKM7:TR?=Mm\oV2FPT0WU
KE-37M2rCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDnTWM2OD1yLkS5OVA6KCEQvF2=MXTTRW5ITVJ?
BV-173NUn0doxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYf4SIlLUUN3ME2wMlUxPzl{IDFOwG0>M4rTWHNCVkeHUh?=
MEG-01NECyeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4K2e2lEPTB;MD61NVIyPCBizszNNXvtXXFRW0GQR1XS
LB2241-RCCNGTnWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHzc4VKSzVyPUCuOVM4OThiIN88US=>M3PvVHNCVkeHUh?=
ACHNNVf3NHFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfkZotQUUN3ME2wMlU1ODZ7IDFOwG0>NEnpeXpUSU6JRWK=
CTB-1NY\XV4pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDUTWM2OD1yLkW0PFIhKM7:TR?=NG[w[VlUSU6JRWK=
HT-1080NVHvVGVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzGXIlKSzVyPUCuOVU{PDliIN88US=>M1TS[XNCVkeHUh?=
CHL-1NFvuT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3tWJNQUUN3ME2wMlU2PDZ3IDFOwG0>NVzaRYZNW0GQR1XS
EW-3NVz4THp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfLTWM2OD1yLkW1PVM2KCEQvF2=MkDjV2FPT0WU
ES1MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvjOZlKSzVyPUCuOlc1QThiIN88US=>MnHiV2FPT0WU
KASUMI-1MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\pdWlEPTB;MD63NlM{KCEQvF2=NYnoVpVTW0GQR1XS
SW13MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXCcXRKSzVyPUCuO|M4QThiIN88US=>NWf6fIlmW0GQR1XS
A3-KAWNWW0RZBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTRbm1PUUN3ME2wMlc6OjB6IDFOwG0>NFWzNWZUSU6JRWK=
LB771-HNCMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnKUYhKSzVyPUCuPFMyODRiIN88US=>MofYV2FPT0WU
OC-314MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHL3W4RKSzVyPUCuPFY6PjViIN88US=>NXnhbIk5W0GQR1XS
MLMAMnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjRZ4ZKSzVyPUCuPVA3PzViIN88US=>NYXrdYs4W0GQR1XS
KARPAS-45NUHybJRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYC2PXlxUUN3ME2wMlkzPDZ4IDFOwG0>MkD2V2FPT0WU
CAL-27M2fS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPvTVFOUUN3ME2wMlkzQTB4IDFOwG0>M{XaPXNCVkeHUh?=
SK-NEP-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUn1emhbUUN3ME2wMlk4OjR6IDFOwG0>MVPTRW5ITVJ?
COR-L105MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\uOXFKSzVyPUGuNFA{QTRiIN88US=>NUHH[ml3W0GQR1XS
TI-73MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTFwMEG2OUAh|ryPM{XaSHNCVkeHUh?=
JVM-3NHzCSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrYZpFKSzVyPUGuNFUxOTdiIN88US=>MnPoV2FPT0WU
HAL-01Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjXd5JwUUN3ME2xMlA5QDFiIN88US=>MVHTRW5ITVJ?
QIMR-WILMkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfDenJKSzVyPUGuNFkxPThiIN88US=>MmHGV2FPT0WU
HSC-3MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDWTWM2OD1zLkGxO|g{KCEQvF2=NYeyPVV3W0GQR1XS
KY821NYHKWWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTFwMUOzOVEhKM7:TR?=MXnTRW5ITVJ?
5637MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvqTWM2OD1zLkGzPFA{KCEQvF2=MoTVV2FPT0WU
CAL-33MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zBbWlEPTB;MT6xPVMxOiBizszNM{W4VXNCVkeHUh?=
ES4MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTFwMkC3PUAh|ryPMknLV2FPT0WU
BHYMkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\XVWlEPTB;MT6yNlg6OiBizszNNFLpTmNUSU6JRWK=
LB1047-RCCNWnpW5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTFwMkO3PFUhKM7:TR?=MUHTRW5ITVJ?
H4NGnMN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnETZBxUUN3ME2xMlI1OjV3IDFOwG0>NFvGSolUSU6JRWK=
RPMI-8866MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPMXlU4UUN3ME2xMlI3OTB4IDFOwG0>NIK2Xm9USU6JRWK=
HO-1-N-1NEP2cIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTW[GJKSzVyPUGuNlY{PjliIN88US=>M37nW3NCVkeHUh?=
BB30-HNCNIL6XHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYL4XWt7UUN3ME2xMlI5PzF2IDFOwG0>MofSV2FPT0WU
PC-14NILPe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1:0NWlEPTB;MT6yPVIxPSBizszNM4n5bnNCVkeHUh?=
NUGC-3MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTFwMkmzOVYhKM7:TR?=NVLm[3NqW0GQR1XS
A4-FukMmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTFwM{C3NFQhKM7:TR?=M4LYXnNCVkeHUh?=
MHH-NB-11M17DeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTFwM{GzPFMhKM7:TR?=MlrYV2FPT0WU
KOSC-2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTFwM{G3O|UhKM7:TR?=NXztT2R4W0GQR1XS
A498MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTFwNECxNVMhKM7:TR?=MUPTRW5ITVJ?
KG-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkmwTWM2OD1zLkSxNlc{KCEQvF2=M33hWnNCVkeHUh?=
DELMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvtTWM2OD1zLkSzOlU4KCEQvF2=MnHaV2FPT0WU
EW-16NV25Sm54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHj6VGlKSzVyPUGuOFM6PzNiIN88US=>NGnSUIZUSU6JRWK=
BPH-1NXjEV4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2fJe2lEPTB;MT60OFgxPSBizszNMXTTRW5ITVJ?
JARMlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTFwNEmzOkAh|ryPNHLacVlUSU6JRWK=
J-RT3-T3-5MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXpU29KSzVyPUGuOVE4OjJiIN88US=>NF3DRWJUSU6JRWK=
A375MmnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoryTWM2OD1zLkWxO|czKCEQvF2=NHHwdGJUSU6JRWK=
SW954MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDReJRvUUN3ME2xMlU2ODB5IDFOwG0>M3\MfXNCVkeHUh?=
Ca9-22NFLuNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjnOotTUUN3ME2xMlU3OjZiIN88US=>NYP5bm1kW0GQR1XS
D-566MGM4DDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXWOWZOUUN3ME2xMlU4OTV3IDFOwG0>MkD4V2FPT0WU
SCC-15NV\mNZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTFwNkG4NFQhKM7:TR?=M{j6fnNCVkeHUh?=
HD-MY-ZNGPQNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\pVZRmUUN3ME2xMlY{PTh2IDFOwG0>MoTXV2FPT0WU
HT-1376MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LIdmlEPTB;MT62OFM3KCEQvF2=NFrufHNUSU6JRWK=
CAL-54NVewNZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnRTWM2OD1zLk[1O|A6KCEQvF2=MYHTRW5ITVJ?
ONS-76MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljOTWM2OD1zLk[3OVUyKCEQvF2=M{TTTHNCVkeHUh?=
EFO-27Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\kbmlEPTB;MT62PFkzKCEQvF2=NVvYc2xyW0GQR1XS
769-PNGrofXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLLeZFKSzVyPUGuOlk2QTZiIN88US=>NF3NOHZUSU6JRWK=
MV-4-11MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfNWnF[UUN3ME2xMlY6QDV4IDFOwG0>M1zNOXNCVkeHUh?=
NKM-1NELUZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3vc4V3UUN3ME2xMlcyQDB{IDFOwG0>MmLwV2FPT0WU
LOXIMVIM{fne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF:0fm5KSzVyPUGuO|Q2QTliIN88US=>MWHTRW5ITVJ?
KYSE-140NYHEZ3FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7nUHRKSzVyPUGuO|U3PTViIN88US=>M3zlOHNCVkeHUh?=
ES5MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVfyV2JLUUN3ME2xMlg3PzR5IDFOwG0>NHjXPG5USU6JRWK=
BB65-RCCM2Lr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDhe3VLUUN3ME2xMlg6QDR7IDFOwG0>MnSyV2FPT0WU
HNMlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTFwOEm4O|QhKM7:TR?=MV3TRW5ITVJ?
A101DNH3BV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXBN3R{UUN3ME2xMlk{PjJ6IDFOwG0>NILTOJVUSU6JRWK=
LoVoMk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\XTGVKSzVyPUGuPVc3PzliIN88US=>NHrOPXZUSU6JRWK=
NCI-H526NI[2flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTwTWM2OD1zLkm5N|I2KCEQvF2=NFLkUXpUSU6JRWK=
NCI-H1693NGexfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTFwOUm4PFghKM7:TR?=MmTTV2FPT0WU
OVCAR-4NXfiXmZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;hTWM2OD1{LkCwOFM2KCEQvF2=M3\kXHNCVkeHUh?=
SK-HEP-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoP3TWM2OD1{LkCwO|Q2KCEQvF2=M33wOXNCVkeHUh?=
C2BBe1MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJwMEOzO|IhKM7:TR?=NYHTcGtQW0GQR1XS
MEL-JUSOMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHEfpNYUUN3ME2yMlA1PDZ2IDFOwG0>M4\tU3NCVkeHUh?=
MOLT-16MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTJwMEewOVghKM7:TR?=NV[0OldTW0GQR1XS
NBsusSRNWLObFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVnITodWUUN3ME2yMlA6QDh7IDFOwG0>NFf6em9USU6JRWK=
TK10MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPZc|FqUUN3ME2yMlE{PDV6IDFOwG0>MkHpV2FPT0WU
CAL-39NUW3Xm1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\P[2lEPTB;Mj6xOFQ5KCEQvF2=Ml7aV2FPT0WU
NCI-H2030M3;YfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi5TFVKSzVyPUKuNVg6PzNiIN88US=>NVXERZVOW0GQR1XS
HCT-116NHv5VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\zWplKSzVyPUKuNlI6QDRiIN88US=>MX\TRW5ITVJ?
HTC-C3NYGwWVhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTJwMk[4NlQhKM7:TR?=NXvLfYhbW0GQR1XS
TYK-nuMnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlnlTWM2OD1{LkOwPVA6KCEQvF2=M1H1d3NCVkeHUh?=
FADUMmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnr1TWM2OD1{LkOyNlk3KCEQvF2=NIf2WWVUSU6JRWK=
A431NH:xbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vL[mlEPTB;Mj6zO|AzPSBizszNM1vxVXNCVkeHUh?=
TE-11NGj0WYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJwM{iwNVkhKM7:TR?=NYGxflNEW0GQR1XS
CAL-12TMnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT0TWM2OD1{LkSwOFE4KCEQvF2=NIL4cVhUSU6JRWK=
DBNX7lbmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJwNEK4OlkhKM7:TR?=NIr6PXFUSU6JRWK=
L-363NInDdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTJwNEO1NFchKM7:TR?=MYfTRW5ITVJ?
MSTO-211HMk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M375UWlEPTB;Mj62OlM6OSBizszNMYHTRW5ITVJ?
SK-UT-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTJwN{G0NFYhKM7:TR?=M{LvfHNCVkeHUh?=
RPMI-8226NIm0U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTJwN{OxOlQhKM7:TR?=NGjPdGFUSU6JRWK=
SF295Mo\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jwZWlEPTB;Mj63OFMyKCEQvF2=MWLTRW5ITVJ?
OS-RC-2M3npXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3kTWM2OD1{Lke2Olc{KCEQvF2=MXvTRW5ITVJ?
SK-MEL-24NVPWN2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfEXJpKSzVyPUKuO|gzOjRiIN88US=>NUDjOXB2W0GQR1XS
COR-L23MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTJwN{m0OlQhKM7:TR?=Ml3MV2FPT0WU
MHH-PREB-1NYjaXXk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XPbmlEPTB;Mj64NFE3OSBizszNNWrTfFBsW0GQR1XS
SK-N-DZNIG5bFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTJwOEG2N|ghKM7:TR?=MXjTRW5ITVJ?
OMC-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTJwOEWwNFMhKM7:TR?=MnXzV2FPT0WU
SK-MEL-2NGXpUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\jNYpKSzVyPUKuPFkzPDNiIN88US=>MX;TRW5ITVJ?
SASNUPHfWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTJwOUm0NVUhKM7:TR?=NULhdpdGW0GQR1XS
EPLC-272HNWPrVoJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX:4bY5wUUN3ME2zMlAxOjN3IDFOwG0>M3;NRXNCVkeHUh?=
8505CM1j6U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHESVBKSzVyPUOuNVA{ODFiIN88US=>MUnTRW5ITVJ?
EW-11Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XSZWlEPTB;Mz6xOFI4PyBizszNMn\pV2FPT0WU
YKG-1Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInLT5RKSzVyPUOuNVQ4ODZiIN88US=>NUWyeIFWW0GQR1XS
EC-GI-10M3KxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jRcmlEPTB;Mz6xO|I3OyBizszNNIr4W3lUSU6JRWK=
SK-LU-1MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTNwMUi0NVghKM7:TR?=NWPwfo0zW0GQR1XS
P30-OHKMkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEKy[WZKSzVyPUOuNlAyOTdiIN88US=>NEXsT3pUSU6JRWK=
T-24NVjJVGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTNwMkG4NVQhKM7:TR?=NHnYUmxUSU6JRWK=
HSC-2MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnvqTWM2OD1|LkKyNlMzKCEQvF2=MV;TRW5ITVJ?
SK-MES-1NYXGXGc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXf2ZpJLUUN3ME2zMlI1QDJ7IDFOwG0>NUCwb21pW0GQR1XS
SW48NEDCe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfpS|lKSzVyPUOuNlU1QDZiIN88US=>Mmj3V2FPT0WU
ME-180M2K1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmfhTWM2OD1|LkK2NFUyKCEQvF2=M33YV3NCVkeHUh?=
NCI-H2009MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXWTWM2OD1|LkK5NFEhKM7:TR?=NHv1ZpVUSU6JRWK=
HL-60NVrqW5JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHWTWM2OD1|LkK5NVMhKM7:TR?=MXnTRW5ITVJ?
NCI-N87MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vtbmlEPTB;Mz6zNFE4OiBizszNM3XXO3NCVkeHUh?=
GMS-10M2rHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIH1O3ZKSzVyPUOuN|QxQDZiIN88US=>MnWyV2FPT0WU
SCHM{DSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MknXTWM2OD1|LkSwPFQ1KCEQvF2=M4i2VXNCVkeHUh?=
C-33-AM3T0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHK3epBKSzVyPUOuOFE1OjFiIN88US=>M3WxenNCVkeHUh?=
NCI-H1703MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDzTWM2OD1|LkSxPFEzKCEQvF2=NWXBVJFjW0GQR1XS
A427NG\rcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTNwNE[xNlQhKM7:TR?=M3HUZ3NCVkeHUh?=
MOLT-4M3nUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYG0RZpPUUN3ME2zMlQ5OTl7IDFOwG0>NVHEN4JRW0GQR1XS
NCI-H1792NGG2coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrmTWM2OD1|LkS5PFAzKCEQvF2=MYLTRW5ITVJ?
NCI-H1650MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{H2XGlEPTB;Mz61O|I6KCEQvF2=MojuV2FPT0WU
H-EMC-SSNFL6bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTNwNUi1OlkhKM7:TR?=NUHiPVMxW0GQR1XS
SW982NUHEWVBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoOzTWM2OD1|LkW4PFI6KCEQvF2=Mkf2V2FPT0WU
DSH1M3G2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljaTWM2OD1|Lk[0NVIzKCEQvF2=MULTRW5ITVJ?
NOS-1NHziN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTNwNkSyO|YhKM7:TR?=M4nGWHNCVkeHUh?=
BT-549MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXW3UGNKUUN3ME2zMlY4QDV2IDFOwG0>MlHVV2FPT0WU
HuCCT1MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVX1eYp5UUN3ME2zMlc1OTd5IDFOwG0>MmK1V2FPT0WU
NCI-H1755NYj5SVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rPVGlEPTB;Mz65Olk4OSBizszNM3zUNXNCVkeHUh?=
KYSE-450NV3SOXYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTNwOU[5PVchKM7:TR?=NEHUN|hUSU6JRWK=
MIA-PaCa-2MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{C1emlEPTB;Mz65O|I6KCEQvF2=MVrTRW5ITVJ?
U-266NHqyb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfxTWM2OD1|Lkm3OFgyKCEQvF2=NHPFeYtUSU6JRWK=
MewoNVKxUYxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTRwME[zOlEhKM7:TR?=MVPTRW5ITVJ?
KYSE-520NHW0cZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnOb3NKSzVyPUSuNFk4QTliIN88US=>M17PSnNCVkeHUh?=
MN-60M4\BTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfjTWM2OD12LkGwOVAyKCEQvF2=NFKxepJUSU6JRWK=
Ramos-2G6-4C10NUH6WWxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfLTWM2OD12LkG2O|M6KCEQvF2=MnPaV2FPT0WU
SK-MEL-1NFPXfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLqdIdqUUN3ME20MlE5Pjl3IDFOwG0>MlzRV2FPT0WU
ABC-1NInqZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mof4TWM2OD12LkKzN|M{KCEQvF2=MWjTRW5ITVJ?
CAKI-1M3vNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLJTWM2OD12LkK0OVcyKCEQvF2=MnfrV2FPT0WU
HOSNGTrb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVjJR|UxRTRwMkmxOFEhKM7:TR?=MnrpV2FPT0WU
SN12CMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf2TWM2OD12LkO0NlQ1KCEQvF2=NEDDOpVUSU6JRWK=
NB13MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTRwM{ezOVUhKM7:TR?=MWrTRW5ITVJ?
M14NVPkWWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTRwNEi3PVIhKM7:TR?=NH\ub2pUSU6JRWK=
GP5dMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{P2dWlEPTB;ND61NFEzKCEQvF2=NGnXfWZUSU6JRWK=
NCI-H720MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELKdFlKSzVyPUSuOVM3OTJiIN88US=>NHvRVFJUSU6JRWK=
D-423MGNYTJeZFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTRwNUO5NlQhKM7:TR?=MkfqV2FPT0WU
ChaGo-K-1M4rOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjqTWM2OD12LkW5OVU6KCEQvF2=MVXTRW5ITVJ?
MEL-HOMl;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTRwNkGyOlEhKM7:TR?=MUHTRW5ITVJ?
MHH-ES-1NUSzNmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\vS3ZQUUN3ME20MlYzPDFzIDFOwG0>NFXabGdUSU6JRWK=
KYSE-270NF\J[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjYdW1KSzVyPUSuOlUyOjZiIN88US=>NFrFb4hUSU6JRWK=
GI-ME-NNIGzbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrFTWM2OD12LkexNlkyKCEQvF2=NV\u[VlrW0GQR1XS
HOP-92MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnoZlJjUUN3ME20MlgyOzd7IDFOwG0>Mk\EV2FPT0WU
MKN1NGjEXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fYfWlEPTB;ND64N|kyPCBizszNM3T3bnNCVkeHUh?=
ML-2NF36RVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWKwVZczUUN3ME20Mlg2PjJ4IDFOwG0>MV7TRW5ITVJ?
RO82-W-1M{jxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIHoUldKSzVyPUSuPVI6QCBizszNMW\TRW5ITVJ?
G-361M4fOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUG3cpFOUUN3ME21MlAyODB|IDFOwG0>M4f5UnNCVkeHUh?=
HC-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmn0TWM2OD13LkCzNlkyKCEQvF2=NIi0boZUSU6JRWK=
EW-24NGDjZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkm4TWM2OD13LkC0NFM5KCEQvF2=NUPubHhVW0GQR1XS
HuP-T4MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEPXOVdKSzVyPUWuNVQ{OzRiIN88US=>M{fxfXNCVkeHUh?=
8-MG-BANYnzPJVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTVwM{SyPEAh|ryPNGHWdphUSU6JRWK=
HGC-27MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vZPWlEPTB;NT6zO|Y5OiBizszNNVHlT41kW0GQR1XS
TE-12MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnwTWM2OD13LkSxOVg2KCEQvF2=NHPtcG9USU6JRWK=
GT3TKBM3rVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoX5TWM2OD13LkS0NlEzKCEQvF2=MUXTRW5ITVJ?
DOHH-2MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3rTWM2OD13LkS1PVg3KCEQvF2=NEfnOm5USU6JRWK=
Ca-SkiNGjN[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTVwNE[xNVUhKM7:TR?=MUnTRW5ITVJ?
A172MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTVwNUS5NlUhKM7:TR?=MlfrV2FPT0WU
EGI-1M2XsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLQTWM2OD13LkW4PVM5KCEQvF2=MUnTRW5ITVJ?
MZ2-MELM1i3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnve|dtUUN3ME21MlYyPDh4IDFOwG0>NVvpbpRQW0GQR1XS
SW1710M2La[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XPUWlEPTB;NT62PVA6OSBizszNNFuzdWdUSU6JRWK=
HT-144MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3QTWM2OD13LkeyOlg2KCEQvF2=MoT0V2FPT0WU
PA-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzFTWM2OD13LkixPFk{KCEQvF2=M3rkcXNCVkeHUh?=
HCC1937NVK5eVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTVwOEO5NlkhKM7:TR?=M1fm[3NCVkeHUh?=
SK-OV-3MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTVwOUGxNlEhKM7:TR?=MnHxV2FPT0WU
K5MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnezTWM2OD14LkC1NVchKM7:TR?=NYfQfJM6W0GQR1XS
NMC-G1M4HQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTZwMEe3PVchKM7:TR?=MlPaV2FPT0WU
MDA-MB-361MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DQVWlEPTB;Nj6wPVI3OSBizszNNHfk[3RUSU6JRWK=
EKVXM3;YZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHle2VqUUN3ME22MlE{PTBzIDFOwG0>Mly1V2FPT0WU
ES7NV3UdFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTvRZJKSzVyPU[uNVYyOTViIN88US=>MYnTRW5ITVJ?
KS-1NHW1TmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rINGlEPTB;Nj6xO|k6OyBizszNMnn0V2FPT0WU
NCI-H661MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXJdXNEUUN3ME22MlE5ODhzIDFOwG0>M3i5d3NCVkeHUh?=
ES8M{TKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4SxXGlEPTB;Nj6xPFA5OiBizszNNYLlfpNpW0GQR1XS
NCI-H23M37zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLZcnJ{UUN3ME22MlIyQDF4IDFOwG0>NU\KZopNW0GQR1XS
T47DNF7qZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{n6[mlEPTB;Nj6yOlQ2PyBizszNM4C2ZXNCVkeHUh?=
A2780MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfWbJlKSzVyPU[uN|c4ODFiIN88US=>MYPTRW5ITVJ?
SCC-4M3naPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrWTWM2OD14LkSzOVYyKCEQvF2=M4fvPXNCVkeHUh?=
VA-ES-BJNWXucXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfDRnRMUUN3ME22Mlk4ODR|IDFOwG0>Mk\0V2FPT0WU
no-11MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfxO2pKUUN3ME23MlE3PDFiIN88US=>NGXOS|NUSU6JRWK=
KU-19-19MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\FcIJOUUN3ME23MlE3PDd4IDFOwG0>M1W4fXNCVkeHUh?=
MKN45MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGjDVXBKSzVyPUeuNVg3QTliIN88US=>MmHRV2FPT0WU
SCC-25NFjVUmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NY\xeo1TUUN3ME23MlI{PDF2IDFOwG0>M2fm[HNCVkeHUh?=
ETK-1MmO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLHV2hKSzVyPUeuNlU2OTRiIN88US=>NF:5SY9USU6JRWK=
COR-L88MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlf0TWM2OD15LkK5N|E6KCEQvF2=MV;TRW5ITVJ?
8305CM3e5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;PTWM2OD15LkOyOFkzKCEQvF2=NU\n[pNqW0GQR1XS
Detroit562MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTdwM{K1NFYhKM7:TR?=NYLLZng3W0GQR1XS
SNU-449MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3mxXGlEPTB;Nz6zO|Y2OSBizszNMmDBV2FPT0WU
A704NIfndXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTdwM{iyO|ghKM7:TR?=MY\TRW5ITVJ?
D-502MGNYLGNJo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmSzTWM2OD15LkO4OFc{KCEQvF2=M1L1Z3NCVkeHUh?=
NCI-H2228NEHWNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnW2TWM2OD15LkSxOFU5KCEQvF2=NV\Kfm5rW0GQR1XS
CHP-212NX:4XJA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnu0TWM2OD15LkWxPFk3KCEQvF2=MVfTRW5ITVJ?
VMRC-RCZM4LqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfNeW5KSzVyPUeuOVkxPjZiIN88US=>NWTYXVZjW0GQR1XS
RPMI-2650Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHe4RXlKSzVyPUeuO|A{OTJiIN88US=>Mk[2V2FPT0WU
HCC2218MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HqRmlEPTB;Nz63NlI2QCBizszNMV7TRW5ITVJ?
GCTMoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVz2V5VSUUN3ME23MlgzOTd{IDFOwG0>M{LIPXNCVkeHUh?=
SW780NHLER4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGL2SI1KSzVyPUeuPVkxPiBizszNNFeyem9USU6JRWK=
KMOE-2MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRThwMESwO{Ah|ryPM33TcnNCVkeHUh?=
KYSE-180Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DyZ2lEPTB;OD6wPFY1QCBizszNMmPBV2FPT0WU
TE-1NVKzPY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvmV|BKSzVyPUiuNVExPTdiIN88US=>MXzTRW5ITVJ?
OAW-42NEHYcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrGTWM2OD16LkK1OFk3KCEQvF2=MX\TRW5ITVJ?
VM-CUB-1M33OO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnzTWZyUUN3ME24MlI5OzZ2IDFOwG0>NFj4N4pUSU6JRWK=
ECC10M3ThdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnH1TWM2OD16LkK4N|k4KCEQvF2=MWTTRW5ITVJ?
SW1573NVHyc2dzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXZNGROUUN3ME24MlQ1PDZ3IDFOwG0>MoHUV2FPT0WU
NCI-H1299M{W4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3EenVYUUN3ME24MlU6Pzd2IDFOwG0>NUDvOIQ4W0GQR1XS
ALL-PONVPDXodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRThwNk[1PVchKM7:TR?=MVvTRW5ITVJ?
OVCAR-5MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{H0dGlEPTB;OD63O|YzPSBizszNNYnseW03W0GQR1XS
NCI-SNU-5NXz3dItoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmDUTWM2OD16LkizNFAyKCEQvF2=MVXTRW5ITVJ?
NCI-H2342M1PNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\zTWM2OD16LkizNVAyKCEQvF2=NHTzWIJUSU6JRWK=
RPMI-7951MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXu0NnZpUUN3ME24Mlg1OTV5IDFOwG0>NXLsV4p6W0GQR1XS
RCM-1M{SydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W1U2lEPTB;OT6wPFE1PSBizszNMkDIV2FPT0WU
DaoyMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHaTWM2OD17LkGyNFI5KCEQvF2=M2r0NHNCVkeHUh?=
HCC1395M{jPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn[2TWM2OD17LkOwPFk3KCEQvF2=NUi5WZc1W0GQR1XS
786-0NVyyfJFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTlwM{[wNlYhKM7:TR?=MV\TRW5ITVJ?
GAMGNYrqS|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV23fHBDUUN3ME25MlY2PTN2IDFOwG0>MWTTRW5ITVJ?
HCC1954NHrU[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnWzTWM2OD17Lki1PFU6KCEQvF2=NHLsRnNUSU6JRWK=
NCI-H1838MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37TZWlEPTB;OT65NFM4OSBizszNMYjTRW5ITVJ?
SW620MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFSxOGxKSzVyPUmuPVU{PTdiIN88US=>M2\ISnNCVkeHUh?=
NCI-H358NIjBZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1z5Z2lEPTB;MUCuOFE6PyBizszNMYHTRW5ITVJ?
NCI-H1793M3;yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4P4c2lEPTB;MUCuOFI1QCBizszNMojTV2FPT0WU
NCI-H1666MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXUZ|cyUUN3ME2xNE41OzV3IDFOwG0>M3flU3NCVkeHUh?=
MZ7-melNWi5cHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTFyLkS3OVMhKM7:TR?=NIXEUHhUSU6JRWK=
MDA-MB-175-VIINFXBcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\FTWM2OD1zMD62N|k3KCEQvF2=MUHTRW5ITVJ?
COLO-829M2nLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3wTWM2OD1zMD64NFA1KCEQvF2=MorKV2FPT0WU
RVH-421NVO2dI95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4Tm[GlEPTB;MUGuNVUzKCEQvF2=NETRWFhUSU6JRWK=
A549M{i4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLCd5BuUUN3ME2xNU4zPDd6IDFOwG0>NY[xSVRTW0GQR1XS
DJM-1NF[5TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLxTWM2OD1zMT6zPFM{KCEQvF2=MY\TRW5ITVJ?
IST-MEL1NWfJemZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXBTWM2OD1zMT63N|E6KCEQvF2=M3LEU3NCVkeHUh?=
BENNYPVWVdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvYTWM2OD1zMT63OFAzKCEQvF2=MVrTRW5ITVJ?
KM12NWjzVY55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnRbHZNUUN3ME2xNU46ODlzIDFOwG0>NXyzNXlqW0GQR1XS
HuO9NGL3U4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF{LkC2OlYhKM7:TR?=NFK3bFBUSU6JRWK=
U-2-OSM13CbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLWOFJKSzVyPUGyMlA5QTNiIN88US=>MUfTRW5ITVJ?
RH-1MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrPTWM2OD1zMj60OFczKCEQvF2=NG\aWIVUSU6JRWK=
NCI-H1048M3T1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIDRdGdKSzVyPUGyMlU2ODZiIN88US=>Mkf2V2FPT0WU
Mo-TM1\PRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;HTpNKSzVyPUGyMlc{ODdiIN88US=>NHjVRlRUSU6JRWK=
KYSE-150NXH2R|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYf3OYRjUUN3ME2xNk44PDV3IDFOwG0>NH3x[3dUSU6JRWK=
A388NGPEV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;2RohKSzVyPUGyMlc4OTNiIN88US=>NWfYN|ZmW0GQR1XS
NCI-SNU-1M37wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXLOFVKSzVyPUGyMlgxPDZiIN88US=>MmflV2FPT0WU
HELMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVj0NYhbUUN3ME2xNk45OjF{IDFOwG0>MkHVV2FPT0WU
UM-UC-3M{HNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\UTWM2OD1zMj64PFc1KCEQvF2=M2WyfHNCVkeHUh?=
TGBC24TKBNHXJd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF|LkCyOlchKM7:TR?=Mlj0V2FPT0WU
SW626NGSw[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2jpcGlEPTB;MUOuNlQ5PSBizszNNUTvPIxCW0GQR1XS
ES6MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTF|LkK1NVIhKM7:TR?=NW\KXZlQW0GQR1XS
NCI-H2029M3;Tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TudWlEPTB;MUOuPFExQCBizszNNEPuPZpUSU6JRWK=
RXF393M2nPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXS0PVg2UUN3ME2xN{46QTJ5IDFOwG0>NXq1fFBZW0GQR1XS
HMV-IIMofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTF2LkC3PEAh|ryPMUnTRW5ITVJ?
EW-22MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLVTndIUUN3ME2xOE4yPTB{IDFOwG0>MVHTRW5ITVJ?
AsPC-1NE\mW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHqSoxTUUN3ME2xOE42PjRiIN88US=>MnHRV2FPT0WU
COLO-678NETpTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\aXnFtUUN3ME2xOE44OjdzIDFOwG0>NIm1VWxUSU6JRWK=
HCT-15NFPF[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV65RmQ5UUN3ME2xOE45QDV3IDFOwG0>NYOzNY01W0GQR1XS
HCE-TNWP4dIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2D4ZWlEPTB;MUSuPFg4PCBizszNMoi5V2FPT0WU
SF539NHyyR2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF3LkC2OFMhKM7:TR?=MnX3V2FPT0WU
AU565NFHUPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[2d2lEPTB;MUWuNlA6PiBizszNM1ziXnNCVkeHUh?=
JVM-2MlHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnkR|J5UUN3ME2xOU4zPjhzIDFOwG0>NWT6OJRTW0GQR1XS
CaR-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTHUYpYUUN3ME2xOU41PDF{IDFOwG0>MY\TRW5ITVJ?
23132-87M2Hkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLnTWM2OD1zNT64OFk2KCEQvF2=NHfQPWJUSU6JRWK=
A673NVXBdoJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M17GV2lEPTB;MUWuPVY{PiBizszNNV3wfVhCW0GQR1XS
KYSE-410M{HnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2T3[GlEPTB;MU[uNFI6KCEQvF2=M2fkdXNCVkeHUh?=
TE-9Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;mUmFDUUN3ME2xOk4xPjJiIN88US=>MWDTRW5ITVJ?
LU-139MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHo[HN7UUN3ME2xOk4yQDJ|IDFOwG0>NIXCeYNUSU6JRWK=
GCIYM1nHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrVU29PUUN3ME2xOk4yQTF4IDFOwG0>MoDXV2FPT0WU
JEG-3M{Lydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXGwdWpCUUN3ME2xOk4zPSBizszNM4\VcnNCVkeHUh?=
RT-112M{HBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTF4LkSxOFMhKM7:TR?=NWjyVoNNW0GQR1XS
COLO-680NNITNNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTF4LkWxNFghKM7:TR?=NXPMO|NjW0GQR1XS
LU-134-AMmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHj6fWhKSzVyPUG2Mlk5QTNiIN88US=>NV\1T|V1W0GQR1XS
MFM-223M2TpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrabmdKSzVyPUG3MlE2OzViIN88US=>NVK5WVZUW0GQR1XS
SF126NXrOPVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzVTWM2OD1zNz6xO|AyKCEQvF2=NWTtSldoW0GQR1XS
NCI-H28NFGydWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjoVpp{UUN3ME2xO{4zODZ4IDFOwG0>MmTkV2FPT0WU
BFTC-905NFrTXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHaTlNKSzVyPUG3MlQ5OzJiIN88US=>NXX1[lczW0GQR1XS
SCC-9M3LjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXHTWM2OD1zNz62Nlg2KCEQvF2=MnLJV2FPT0WU
KNS-62MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLtTWM2OD1zNz62OlI6KCEQvF2=MYLTRW5ITVJ?
Hs-578-TNIK3VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkS1TWM2OD1zNz64NVQ6KCEQvF2=MkWyV2FPT0WU
D-336MGMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\RUmlEPTB;MUeuPFI6PCBizszNMU\TRW5ITVJ?
NCI-H82M3O5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTF6LkCxPFMhKM7:TR?=Mlq2V2FPT0WU
EFM-19MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4X3TGlEPTB;MUiuNFU4PyBizszNMn3PV2FPT0WU
TGBC11TKBMojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk[yTWM2OD1zOD6xNFIyKCEQvF2=Mk\BV2FPT0WU
HEC-1MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjhR25KSzVyPUG4MlI6OThiIN88US=>NFnmfI5USU6JRWK=
HuP-T3Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTF6LkW5NlkhKM7:TR?=NHHlSVZUSU6JRWK=
SF268M4DtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrKdGcyUUN3ME2xPE43PzB{IDFOwG0>M2rhPHNCVkeHUh?=
COLO-792NVPEUoZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTF6Lke5PVchKM7:TR?=MlPKV2FPT0WU
HLEMmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTF6LkizN|EhKM7:TR?=NU\4fYdOW0GQR1XS
A204NWj0NHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mme5TWM2OD1zOD65NVY1KCEQvF2=M4\kcnNCVkeHUh?=
CAL-72MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nkPGlEPTB;MUmuNFg4PyBizszNM4\aT3NCVkeHUh?=
U031M4\QPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEi5e2NKSzVyPUG5MlQ6ODliIN88US=>NIjZPJBUSU6JRWK=
FTC-133MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTF7LkmzNFQhKM7:TR?=NHfGem5USU6JRWK=
SK-MEL-28NW[1Z45KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLrOHVoUUN3ME2yNE4{PzZzIDFOwG0>NF2xR2FUSU6JRWK=
KGNNUXWR2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJyLkS2PVkhKM7:TR?=MWfTRW5ITVJ?
HCC2998NEnpS|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTJzLkO5NlYhKM7:TR?=MXPTRW5ITVJ?
GOTONHHqV4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXRSGhnUUN3ME2yNU41QDViIN88US=>Mn3TV2FPT0WU
AGSMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPnTXdKSzVyPUKxMlg1PTFiIN88US=>NYnUT45zW0GQR1XS
EW-13MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJ{LkGwNlIhKM7:TR?=NUH3VldVW0GQR1XS
P12-ICHIKAWANFPIUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTJ{LkG2NFMhKM7:TR?=MYTTRW5ITVJ?
NCI-H1395MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkO1TWM2OD1{Mj6yPVA4KCEQvF2=MoK1V2FPT0WU
A2058MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\4PY1KSzVyPUKyMlQ{PCBizszNNYe0TZhkW0GQR1XS
SH-4MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTJ{LkewOFUhKM7:TR?=NUfZbYg4W0GQR1XS
DoTc2-4510MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDaNHVKUUN3ME2yN{43PDd{IDFOwG0>NFnXTHpUSU6JRWK=
MMAC-SFNVvs[YJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYL4PHRmUUN3ME2yN{43QTFzIDFOwG0>Mk\jV2FPT0WU
NCI-H510AM{XnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXSTWM2OD1{Mz63PVM6KCEQvF2=M{PBXHNCVkeHUh?=
HDLM-2MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTFc4dKSzVyPUK0MlE1PiBizszNMlr6V2FPT0WU
KINGS-1NXXXW5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfoTWM2OD1{ND6yOFIhKM7:TR?=NYTJboJxW0GQR1XS
NCI-H1648M1\ObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfOfWpKSzVyPUK0MlQxOjRiIN88US=>M{TWfHNCVkeHUh?=
HCC1187MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mom2TWM2OD1{NT6wNlM2KCEQvF2=M4nH[3NCVkeHUh?=
BALL-1MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3SdXNlUUN3ME2yOU4zODZ{IDFOwG0>MUnTRW5ITVJ?
SBC-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2[1XmlEPTB;MkWuNlk6OyBizszNNWnMWGU5W0GQR1XS
BFTC-909M1fEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTJ3LkO1OVEhKM7:TR?=MXLTRW5ITVJ?
MOLT-13NGnsW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJ3Lk[3OFQhKM7:TR?=MW\TRW5ITVJ?
SW1990MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3PTWM2OD1{NT65OlU2KCEQvF2=M2TPXXNCVkeHUh?=
DK-MGNGDBSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3hdYN3UUN3ME2yOk4xPDR|IDFOwG0>NGT6UXVUSU6JRWK=
TE-8NXfqRphYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nueWlEPTB;Mk[uNFY3QCBizszNM4j4XnNCVkeHUh?=
BeckerMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJ4LkG1O|QhKM7:TR?=M3XhbHNCVkeHUh?=
KYSE-70M1jWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV6xR2MzUUN3ME2yOk42OzF5IDFOwG0>MoTTV2FPT0WU
MKN7NYfTfmR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDKbnlsUUN3ME2yO{44PDd7IDFOwG0>NHG5fHhUSU6JRWK=
D-392MGNFfKdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTJ5Lke2PVQhKM7:TR?=NHnWRm9USU6JRWK=
NH-12M171NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTJ6LkGyNlkhKM7:TR?=M2TLZnNCVkeHUh?=
EW-18MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHMe3VKSzVyPUK4MlIzOThiIN88US=>M4LGc3NCVkeHUh?=
LCLC-97TM1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJ6LkK3OlIhKM7:TR?=M1T3fHNCVkeHUh?=
NCI-H1770NFnhXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIS5W3FKSzVyPUK4MlM2PjZiIN88US=>M2LjenNCVkeHUh?=
BT-20NEO4VJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTJ6LkO2PFUhKM7:TR?=NVzx[pZZW0GQR1XS
DBTRG-05MGM4DzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\zXVhKSzVyPUK4MlQ5OzhiIN88US=>NIOw[JhUSU6JRWK=
HPAF-IINGjkXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3VTIV1UUN3ME2yPE44PzliIN88US=>NV7hRldCW0GQR1XS
SW837NY[0e41lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjM[pdNUUN3ME2yPU4{Ozh3IDFOwG0>Mor3V2FPT0WU
647-VMl7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jDNWlEPTB;MkmuO|AxOyBizszNM37sZnNCVkeHUh?=
J82MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTvTWM2OD1{OT64NFE{KCEQvF2=MXzTRW5ITVJ?
MC116NIDOVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrteGxUUUN3ME2zNE4xPzN|IDFOwG0>MUnTRW5ITVJ?
NCI-H69M37PPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2CxRmlEPTB;M{CuOlA6OyBizszNMoH4V2FPT0WU
NB6MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TYWGlEPTB;M{GuN|YzQSBizszNM4HUSXNCVkeHUh?=
CAL-120M3HWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYr6OoVXUUN3ME2zNk41OzF5IDFOwG0>NUi5eWo1W0GQR1XS
U-87-MGM1XNVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTN|LkCyOVEhKM7:TR?=NVG2eZc6W0GQR1XS
NCI-H1304NXjuPWlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHe1VJZKSzVyPUOzMlA{PTRiIN88US=>NHm1dG5USU6JRWK=
YH-13NHvae4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTN|LkK1N|UhKM7:TR?=M2\le3NCVkeHUh?=
RMG-IM1fIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnVRlJJUUN3ME2zN{41Ojh3IDFOwG0>NFPhRVdUSU6JRWK=
LU-65NWPtXGx7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTN2LkG0NFghKM7:TR?=NV\GXVRuW0GQR1XS
GB-1M1fofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3jNWNKSzVyPUO1MlA4OjliIN88US=>NUnMc2hXW0GQR1XS
DU-4475M2DmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LJXmlEPTB;M{WuNVU2OyBizszNM3Ox[3NCVkeHUh?=
SBC-5M4D1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTN4LkW5NFIhKM7:TR?=NV\s[3JKW0GQR1XS
OE33MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;oepVKSzVyPUO3Mlc2PzdiIN88US=>MmrLV2FPT0WU
C8166M{HWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTN6LkWyOlchKM7:TR?=Mo\ZV2FPT0WU
COLO-684MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTN6Lke0NlghKM7:TR?=Ml64V2FPT0WU
NCI-H1155NUjic4c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1riN2lEPTB;M{muNFQ4OSBizszNMUXTRW5ITVJ?
ATN-1M1exRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWn3N|lUUUN3ME2zPU44Pzl{IDFOwG0>NUf3RZk6W0GQR1XS
KARPAS-299MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTN7LkizPUAh|ryPMlmwV2FPT0WU
KNS-81-FDNVfYRWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPP[llnUUN3ME20NE4{PjB2IDFOwG0>M2Lac3NCVkeHUh?=
NCI-H1563M4LS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfRTWM2OD12MT61NFM6KCEQvF2=Mn\mV2FPT0WU
NB14M{\MZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLnTWM2OD12Mj63NlY{KCEQvF2=NUjxcYdsW0GQR1XS
COLO-800NF3ZfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjlN4hlUUN3ME20Nk45PTF5IDFOwG0>MXLTRW5ITVJ?
MS-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrHdJFKSzVyPUSzMlA1QDNiIN88US=>MYLTRW5ITVJ?
OVCAR-8NUnINHhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fXTmlEPTB;NEOuOlgxQSBizszNMWTTRW5ITVJ?
SK-PN-DWNFmx[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTR|Lki3O|YhKM7:TR?=NX\2NWtlW0GQR1XS
G-402MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfHTWM2OD12Mz65NFA3KCEQvF2=NV;Fd|Q2W0GQR1XS
NCI-H2291M2HZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHe5cIxKSzVyPUS0MlgxOTdiIN88US=>NH7xVI9USU6JRWK=
PC-3M3zkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M133WWlEPTB;NEWuPFAzOyBizszNNIXMc3RUSU6JRWK=
NCI-H1581MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoGwTWM2OD12NT65PFg6KCEQvF2=MWfTRW5ITVJ?
SW1116NHnYe|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFW3bZlKSzVyPUS3MlAyQDJiIN88US=>MVfTRW5ITVJ?
ZR-75-30MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnm5TWM2OD12Nz6wNlM6KCEQvF2=MkmxV2FPT0WU
OCI-AML2MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\KfGlEPTB;NEeuNFkyQCBizszNMW\TRW5ITVJ?
MDA-MB-231NXHFeHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTR5Lk[yOFkhKM7:TR?=Mn7tV2FPT0WU
ES3Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfhbZo{UUN3ME20PE4{PTJ7IDFOwG0>NUSz[XZbW0GQR1XS
NCI-H630MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3Pwb2lEPTB;NEmuNVc1OiBizszNNFPKfnVUSU6JRWK=
OE19MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIO5N49KSzVyPUS5MlI6ODJiIN88US=>MoX3V2FPT0WU
NCI-H1573M{XiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTiVFdpUUN3ME20PU43QDZzIDFOwG0>MV\TRW5ITVJ?
EW-1NG\EOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVzMPYxMUUN3ME20PU46ODh2IDFOwG0>NIW4XZFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02810990 Not yet recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto September 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Frequently Asked Questions

  • Question 1
    Can I give S1014 Bosutinib to mice by oral gavage? If so, how to dissolve the drug?

    Answer: For oral gavage, S1014 Bosutinib can be dissolved in 5% Tween 80+0.5% CMC Na at 30 mg/ml as a suspension.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) supplier | purchase Bosutinib (SKI-606) | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) manufacturer | order Bosutinib (SKI-606) | Bosutinib (SKI-606) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us